™ health analytics marketscan ® claims encounters ccae databases Search Results


marketscan ccae  (Optum Inc)
86
Optum Inc marketscan ccae
Marketscan Ccae, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/marketscan/pm41748176-132-57-82
Average 86 stars, based on 1 article reviews
marketscan ccae - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
ccae  (IQVIA Inc)
90
IQVIA Inc ccae
Ccae, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/ccae/10__1186_slash_s40537___023___00857___7-64-9-19
Average 90 stars, based on 1 article reviews
ccae - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ccae  (PharMetrics Inc)
90
PharMetrics Inc ccae
Ccae, supplied by PharMetrics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/ccae/pmc09159118__6707985__f1-14-0-33
Average 90 stars, based on 1 article reviews
ccae - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
chi-square test  (CH Instruments)
90
CH Instruments chi-square test
Chi Square Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/chi+square+test/pmc08357380-136-6-14
Average 90 stars, based on 1 article reviews
chi-square test - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ccae database  (AbbVie Inc)
90
AbbVie Inc ccae database
Ccae Database, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/ccae+database/pm33685322-25-1-17
Average 90 stars, based on 1 article reviews
ccae database - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ccae  (Optum Inc)
86
Optum Inc ccae
Ccae, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/ccae/10__1016_slash_s2665___9913_ascii40_19_ascii41_30075___x-95-4-5
Average 86 stars, based on 1 article reviews
ccae - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
semaglutide vs. glipizide ccae  (IQVIA Inc)
90
IQVIA Inc semaglutide vs. glipizide ccae
Semaglutide Vs. Glipizide Ccae, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/semaglutide+vs++glipizide+ccae/pmc11843465__jamaophthalmol___e246555___s001-246-44-75
Average 90 stars, based on 1 article reviews
semaglutide vs. glipizide ccae - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
amb emr  (IQVIA Inc)
90
IQVIA Inc amb emr
Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; <t>CCAE</t> = <t>Merative™</t> MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
Amb Emr, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/ambemr/pmc11681708-416-14-26
Average 90 stars, based on 1 article reviews
amb emr - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
exenatide  (IQVIA Inc)
90
IQVIA Inc exenatide
Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; <t>CCAE</t> = <t>Merative™</t> MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
Exenatide, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/exenatide/pmc11843465__jamaophthalmol___e246555___s001-259-28-63
Average 90 stars, based on 1 article reviews
exenatide - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
dulaglutide vs. sitagliptin  (IQVIA Inc)
90
IQVIA Inc dulaglutide vs. sitagliptin
Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; <t>CCAE</t> = <t>Merative™</t> MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
Dulaglutide Vs. Sitagliptin, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/dulaglutide+vs++sitagliptin/pmc11843465__jamaophthalmol___e246555___s001-254-53-85
Average 90 stars, based on 1 article reviews
dulaglutide vs. sitagliptin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
semaglutide vs sitagliptin  (PharMetrics Inc)
90
PharMetrics Inc semaglutide vs sitagliptin
Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; <t>CCAE</t> = <t>Merative™</t> MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
Semaglutide Vs Sitagliptin, supplied by PharMetrics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/semaglutide+vs+empagliflozin/pm39976940-76-150-152
Average 90 stars, based on 1 article reviews
semaglutide vs sitagliptin - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
sitagliptin ccae  (IQVIA Inc)
90
IQVIA Inc sitagliptin ccae
Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; <t>CCAE</t> = <t>Merative™</t> MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)
Sitagliptin Ccae, supplied by IQVIA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%E2%84%A2+health+analytics+marketscan+%C2%AE+claims+encounters+ccae+databases/sitagliptin+ccae/pmc11843465__jamaophthalmol___e246555___s001-260-36-75
Average 90 stars, based on 1 article reviews
sitagliptin ccae - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

Journal: BMC Medical Research Methodology

Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

doi: 10.1186/s12874-024-02428-7

Figure Lengend Snippet: Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for IBD primary analysis Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; IBD = irritable bowel diseases (Crohn’s disease or ulcerative colitis); IBD comparator = golimumab, certolizumab pegol, ustekinumab, or vedolizumab; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; Remicade ® (m) = Remicade ® exposure; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

Article Snippet: Databases used in this study are available via license are available for purchase from Merative ® (CCAE), Optum ® (Clinformatics ® and Optum ® EHR), and IQVIA (Pharmetrics and Amb EMR).

Techniques:

Attrition diagrams for inflammatory bowel diseases (IBD); patient attrition counts and proportions after sequential design choices applied Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; RA = rheumatoid arthritis; RA comparator = certolizumab pegol or tocilizumab; Remicade ® (m) = Remicade ® exposure with concurrent methotrexate; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

Journal: BMC Medical Research Methodology

Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

doi: 10.1186/s12874-024-02428-7

Figure Lengend Snippet: Attrition diagrams for inflammatory bowel diseases (IBD); patient attrition counts and proportions after sequential design choices applied Key: Amb EMR = IQVIA Ambulatory Electronic Medical Records; ASMD = absolute standardized mean difference; CCAE = Merative™ MarketScan ® Commercial Database; CI = Confidence Interval; Clinformatics ® = Optum ® De-Identified Clinformatics ® Data Mart Database; EASE = expected absolute systematic error; HR = Hazard ratio; Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data; RA = rheumatoid arthritis; RA comparator = certolizumab pegol or tocilizumab; Remicade ® (m) = Remicade ® exposure with concurrent methotrexate; Target covariate prevalence = prevalence of baseline covariates in the initial Remicade ® exposure cohort before study design restrictions were applied; Analytic covariate prevalence = prevalence of baseline covariates in Remicade ® exposure cohort after study design restrictions were applied (i.e., PS matching)

Article Snippet: Databases used in this study are available via license are available for purchase from Merative ® (CCAE), Optum ® (Clinformatics ® and Optum ® EHR), and IQVIA (Pharmetrics and Amb EMR).

Techniques:

Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for RA primary analysis Key – Target: patients with inflammatory bowel diseases newly exposed to Remicade ® , Comparator: patients with inflammatory bowel diseases newly exposed to [golimumab, certolizumab pegol, ustekinumab, or vedolizumab], CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data

Journal: BMC Medical Research Methodology

Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

doi: 10.1186/s12874-024-02428-7

Figure Lengend Snippet: Empirical equipoise, covariate balance, empirical calibration validity diagnostics and representativeness for RA primary analysis Key – Target: patients with inflammatory bowel diseases newly exposed to Remicade ® , Comparator: patients with inflammatory bowel diseases newly exposed to [golimumab, certolizumab pegol, ustekinumab, or vedolizumab], CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR = Optum ® De-Identified Electronic Health Record; Pharmetrics = IQVIA Adjudicated Health Plan Claims Data

Article Snippet: Databases used in this study are available via license are available for purchase from Merative ® (CCAE), Optum ® (Clinformatics ® and Optum ® EHR), and IQVIA (Pharmetrics and Amb EMR).

Techniques:

Risk of non-infectious uveitis (NIU) among patients with inflammatory bowel diseases (IBD) Key – PS: propensity score, OT: on-treatment, ITT: intention-to-treat, T: Remicade ® new users with IBD, C: golimumab, certolizumab pegol, ustekinumab, or vedolizumab new users with IBD, IR: incidence rate, PYs: person-years, CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR: Optum ® De-Identified Electronic Health Record, Pharmetrics: IQVIA Adjudicated Health Plan Claims Data

Journal: BMC Medical Research Methodology

Article Title: The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade ®

doi: 10.1186/s12874-024-02428-7

Figure Lengend Snippet: Risk of non-infectious uveitis (NIU) among patients with inflammatory bowel diseases (IBD) Key – PS: propensity score, OT: on-treatment, ITT: intention-to-treat, T: Remicade ® new users with IBD, C: golimumab, certolizumab pegol, ustekinumab, or vedolizumab new users with IBD, IR: incidence rate, PYs: person-years, CCAE: Merative™ MarketScan ® Commercial Database, Optum ® EHR: Optum ® De-Identified Electronic Health Record, Pharmetrics: IQVIA Adjudicated Health Plan Claims Data

Article Snippet: Databases used in this study are available via license are available for purchase from Merative ® (CCAE), Optum ® (Clinformatics ® and Optum ® EHR), and IQVIA (Pharmetrics and Amb EMR).

Techniques: